CytoDyn has entered into an agreement to purchase Progenics Pharmaceuticals' proprietary humanized monoclonal antibody HIV viral-entry inhibitor drug candidate, PRO 140, for $3.5m. Upon successful continued clinical development of PRO ...
Tags: CytoDyn, HIV viral-entry inhibitor drug, humanized monoclonal antibody